Early trial aims to boost immune system to fight tough blood cancers
NCT ID NCT02890329
Summary
This early-stage study is testing the safety and best dose of a two-drug combination for people with aggressive forms of blood cancer (myelodysplastic syndrome or acute myeloid leukemia) that have returned or not responded to prior treatments. The trial combines a chemotherapy drug (decitabine) with an immunotherapy drug (ipilimumab) that aims to help the body's own immune system attack the cancer. It is enrolling adults whose cancer has progressed despite previous therapies, including some who have had a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Northside Hospital
Atlanta, Georgia, 30342, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.